Musculoskeletal symptoms including arthralgia and myalgia occur frequently in aging
women, particularly during the transition to menopause, when plasma estrogens …

The introduction of aromatase inhibitor (AI) therapy for the adjuvant treatment of
postmenopausal women with hormone receptor-positive breast cancer has led to a …

Aromatase inhibitors, which offer profound suppression of estrogen synthesis, have been
introduced as long-term adjuvant therapeutic agents for postmenopausal women with breast …

Purpose Aromatase inhibitors (AIs) improve survival in postmenopausal women with
hormone-sensitive breast cancer, but can cause joint pain and stiffness. The purpose of the …

Aromatase inhibitors (AIs) have become widely used as adjuvant therapy for
postmenopausal women with hormone receptor–positive breast cancer. Although the …

Aromatase inhibitors (AIs) are recommended as adjuvant endocrine therapy for
postmenopausal women with hormone-responsive breast cancer. With the widespread use …

For the upfront adjuvant therapy of postmenopausal estrogen receptor–positive breast
cancer, the third-generation aromatase inhibitors (AIS) have shown a more favourable …

Aromatase Inhibitors (AI) are widely used for the adjuvant treatment of hormone receptor
positive breast cancers in the post-menopausal population. AI are often associated with …

Aromatase inhibitors are widely used as adjuvant therapy in postmenopausal women with
hormone receptor-positive breast cancer. While the agents are associated with slightly …

Aromatase inhibitors (AIs) are widely used as an adjuvant endocrine treatment in
postmenopausal women with early-stage breast cancer. Clinical trials have assessed 5 …